Eltrombopag yields 40% response rate in pediatric immune thrombocytopenia
Treatment with the thrombopoietin receptor agonist eltrombopag led to a sustained platelet response in 40% of children and adolescents with chronic immune thrombocytopenia, compared with only 3% of the placebo group, according to a randomized multicenter trial published online in The...
Source: Skin and Allergy News - Category: Dermatology Source Type: news
More News: Allergy | Allergy & Immunology | Children | Dermatology | Pediatrics | Skin | Thrombocytopenia